Cargando…

Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

Fibroblast growth factors 19 and 21 (FGF19 and FGF21) have been implicated, independently, in type 2 diabetes (T2D) but it is not known if their circulating levels correlate with each other or whether the associated hepatic signaling mechanisms that play a role in glucose metabolism are dysregulated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roesch, Stephen L., Styer, Amanda M., Wood, G. Craig, Kosak, Zachary, Seiler, Jamie, Benotti, Peter, Petrick, Anthony T., Gabrielsen, Jon, Strodel, William E., Gerhard, Glenn S., Still, Christopher D., Argyropoulos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321834/ https://www.ncbi.nlm.nih.gov/pubmed/25664662 http://dx.doi.org/10.1371/journal.pone.0116928

Ejemplares similares

A Role for Fibroblast Growth Factor 19 and Bile Acids in Diabetes Remission After Roux-en-Y Gastric Bypass
por: Gerhard, Glenn S., et al.
Publicado: (2013)

An electronic health record-enabled obesity database
por: Wood, G Craig, et al.
Publicado: (2012)

Gene expression profiling in subcutaneous, visceral, and epigastric adipose tissues of patients with extreme obesity
por: Gerhard, Glenn S., et al.
Publicado: (2013)

Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery
por: Still, Christopher D., et al.
Publicado: (2014)

Identification of Novel Clinical Factors Associated with Hepatic Fat Accumulation in Extreme Obesity
por: Gerhard, Glenn S., et al.
Publicado: (2014)

CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading
por: Chu, Xin, et al.
Publicado: (2018)

All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes
por: Lent, Michelle R., et al.
Publicado: (2017)

A Patient-Centered Electronic Tool for Weight Loss Outcomes after Roux-en-Y Gastric Bypass
por: Wood, G. Craig, et al.
Publicado: (2014)

Gastrointestinal Symptoms in Morbid Obesity
por: Huseini, Mustafa, et al.
Publicado: (2014)

The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients
por: Gerhard, Glenn S, et al.
Publicado: (2011)

Modulation of Fibroblast Growth Factor 19 Expression by Bile Acids, Meal Replacement and Energy Drinks, Milk, and Coffee
por: Styer, Amanda M., et al.
Publicado: (2014)

Nutrient Transporter Expression in the Jejunum in Relation to Body Mass Index in Patients Undergoing Bariatric Surgery
por: Irving, Brian A., et al.
Publicado: (2016)

A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains
por: Wood, G. Craig, et al.
Publicado: (2017)

Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long‐Term Risks of Congestive Heart Failure
por: Benotti, Peter N., et al.
Publicado: (2017)

Prior metabolic surgery reduced COVID-19 severity: Systematic analysis from year one of the COVID-19 pandemic
por: Wood, G. Craig, et al.
Publicado: (2023)

Postoperative mesenteric venous thrombosis: Potential complication related to minimal access surgery in a patient with undiagnosed hypercoagulability
por: Sucandy, Iswanto, et al.
Publicado: (2010)

Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes
por: Gerhard, Glenn S, et al.
Publicado: (2018)

AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p
por: Gerhard, Glenn S., et al.
Publicado: (2019)

Changes in Telomere Length 3-5 years after Gastric Bypass Surgery
por: Dersham, Ridge, et al.
Publicado: (2017)

Electronically captured, patient‐reported physical function: an important vital sign in obesity medicine
por: Fleming, J., et al.
Publicado: (2016)

Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways
por: Gerhard, Glenn S., et al.
Publicado: (2018)

Overall outcomes of laparoscopic-assisted ERCP after Roux-en-Y gastric bypass and sphincter of Oddi dysfunction subgroup analysis
por: May, David, et al.
Publicado: (2019)

Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis
por: Gerhard, Glenn S., et al.
Publicado: (2020)

Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD
por: Johnson, Nicholas D., et al.
Publicado: (2021)

Extension of GWAS results for lipid-related phenotypes to extreme obesity using electronic health record (EHR) data and the Metabochip
por: Parihar, Ankita, et al.
Publicado: (2014)

The relationship between specialized pro-resolving lipid mediators, morbid obesity and weight loss after bariatric surgery
por: Schulte, Fabian, et al.
Publicado: (2020)

Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery
por: Noel, Olivier F., et al.
Publicado: (2016)

Response to comment on Lent et al. All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes. Diabetes Care 2017;40:1379–1385
por: Lent, Michelle R., et al.
Publicado: (2018)

Effects of sustained weight loss on outcomes associated with obesity comorbidities and healthcare resource utilization
por: Wood, G. Craig, et al.
Publicado: (2021)

Collateral Weight Loss in Children Living with Adult Bariatric Surgery Patients: A Case Control Study
por: Hirsch, Annemarie G., et al.
Publicado: (2014)

Long-Term Weight-Loss in Gastric Bypass Patients Carrying Melanocortin 4 Receptor Variants
por: Moore, Bryn S., et al.
Publicado: (2014)

Differential Dynamic Properties of Scleroderma Fibroblasts in Response to Perturbation of Environmental Stimuli
por: Xiong, Momiao, et al.
Publicado: (2008)

Consequences of aneuploidy in human fibroblasts with trisomy 21
por: Hwang, Sunyoung, et al.
Publicado: (2021)

Fibroblast growth factor 21 in heart failure
por: Tucker, William, et al.
Publicado: (2022)

Fibroblast growth factor 21 in metabolic syndrome
por: Yang, Ming, et al.
Publicado: (2023)

Fibroblast growth factor 21 and bone homeostasis
por: Tang, Yan, et al.
Publicado: (2023)

Pharmacological Perturbation of Mechanical Contractility Enables Robust Transdifferentiation of Human Fibroblasts into Neurons
por: He, Zheng‐Quan, et al.
Publicado: (2022)

Exercise Increases Serum Fibroblast Growth Factor 21 (FGF21) Levels
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2012)

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
por: Fisher, ffolliott M., et al.
Publicado: (2010)

Liver-brain axis with alcohol: Role of fibroblast growth factor 21 (FGF21)
por: Zhang, Ke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_19ndsd52q9omgp53meuu7c2vq6